In conclusion, our ViT‐based model offers a novel and effective approach for non‐invasive HER2 status assessment in breast cancer, bridging imaging‐derived features with molecular biology to provide clinically relevant insights. The gene discussed is ERBB2; the disease is breast carcinoma.